Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease

Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease

Abstract Serum leucine-rich alpha-2 glycoprotein (LRG) can monitor disease activities during biologics treatment in patients with inflammatory bowel disease (IBD). It is unclear whether the pretreatment serum LRG level can predict clinical effectiveness including serum trough levels of ustekinumab i...

Full description

Saved in:
Bibliographic Details
Main Authors: Takahiro Amano, Takeo Yoshihara, Shinichiro Shinzaki, Yuko Sakakibara, Takuya Yamada, Naoto Osugi, Satoshi Hiyama, Yoko Murayama, Koji Nagaike, Hideharu Ogiyama, Toshio Yamaguchi, Yuki Arimoto, Ichizo Kobayashi, Shoichiro Kawai, Satoshi Egawa, Takashi Kizu, Masato Komori, Yuri Tsujii, Akiko Asakura, Taku Tashiro, Mizuki Tani, Yuriko Otake-Kasamoto, Ryotaro Uema, Minoru Kato, Yoshiki Tsujii, Takahiro Inoue, Tomomi Yamada, Tetsuhisa Kitamura, Atsushi Yonezawa, Hideki Iijima, Yoshito Hayashi, Tetsuo Takehara
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:Scientific Reports
Subjects:
Leucine-rich alpha-2 glycoprotein
Anti-cytokine biologics
Ustekinumab
Biomarker
Inflammatory bowel disease
Online Access:https://doi.org/10.1038/s41598-024-80285-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-024-80285-6

Similar Items